-
Mashup Score: 79
Positive high-level results from an interim analysis of the AMPLIFY Phase III trial showed a fixed duration of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukaemia (CLL). For the secondary endpoint of overall survival (OS),
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Acquisition of Amolyt Pharma completed - 4 month(s) ago
AstraZeneca today announced the successful completion of the acquisition of Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage pipeline and expands on its bone metabolism franchise with the notable addition of eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide with a novel mechanism of action designed to meet key therapeutic goals for
Source: www.astrazeneca.comCategories: General Medicine News, PayerTweet-
For Medical Media/Investors only: Today, @AstraZeneca completed the acquisition of @AmolytPharma. Learn about this news and how it will enable an expansion into rare endocrinology for Alexion, AstraZeneca Rare Disease: https://t.co/QFuZJbXLJo https://t.co/QY08uhQPJC
-
-
Mashup Score: 72
High-level results from the ADJUVANT BR.31 Phase III trial, sponsored by the Canadian Cancer Trials Group (CCTG), showed Imfinzi (durvalumab) did not achieve statistical significance for the primary endpoint of disease-free survival (DFS) versus placebo in early-stage (IB-IIIA) non-small cell lung cancer (NSCLC) after complete tumour resection in patients whose tumours express PD-L1 on 25% or more tumour cells. Susan Galbraith, Executive Vice President, Oncology R & D, AstraZeneca, said: “We are disappoin
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
Phase III ADJUVANT BR.31 study does not meet primary endpoint. Adjuvant durvalumab for resected stage IB-IIIA NSCLC with PD-L1 ≥ 25% did not improve DFS over placebo. Await full data presentation but disappointing. @OncoAlert https://t.co/HG0IWM1vVM https://t.co/dpKt5iETM1
-
-
Mashup Score: 1
Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS) and the key secondary endpoint of overall survival (OS) versus neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer (MIBC). Patients were treated with Imfinzi in combination with neoadjuvant chemotherapy before cystectomy
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
🔥🔥 Imfinzi demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial Congrats to all investigators/patients!👏@OncoAlert https://t.co/UCyGc3TC4J
-
-
Mashup Score: 1
Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS) and the key secondary endpoint of overall survival (OS) versus neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer (MIBC). Patients were treated with Imfinzi in combination with neoadjuvant chemotherapy before cystectomy
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
🔥🔥 Imfinzi demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial Congrats to all investigators/patients!👏@OncoAlert https://t.co/UCyGc3TC4J
-
-
Mashup Score: 1
Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS) and the key secondary endpoint of overall survival (OS) versus neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer (MIBC). Patients were treated with Imfinzi in combination with neoadjuvant chemotherapy before cystectomy
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
🔥🔥 Imfinzi demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial Congrats to all investigators/patients!👏@OncoAlert https://t.co/UCyGc3TC4J
-
-
Mashup Score: 19
AstraZeneca’s Farxiga (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycaemic control in paediatric patients with type-2 diabetes (T2D) aged 10 years and older. 1 The FDA approval was based on positive results from the paediat ric T2NOW Phase III trial. 2 Farxiga was previously approved in the US in adults with T2D as an adjunct to diet and exercise to improve glycaemic control. 1 Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, AstraZenec
Source: www.astrazeneca.comCategories: General Medicine News, CardiologistsTweet-
RT @kamleshkhunti: Dapagliflozin (Farxiga) approved in US for the treatment of paediatric type 2 diabetes https://t.co/2tdP2nlran https://…
-
-
Mashup Score: 8Optimising asthma care for patients and the planet - 6 month(s) ago
Asthma is a chronic disease affecting 262 million people globally, responsible for over 450,000 deaths annually due to its severe respiratory complications and frequent asthma attacks.
Source: www.astrazeneca.comCategories: General Medicine News, Allergy-ImmunologyTweet-
Optimising #asthma care for patients and the environment by developing inhaled respiratory medications with a cutting-edge, eco-friendly propellant that significantly reduces global warming impact. #EcoMedicine #AsthmaCare https://t.co/7pjhrSYGJE https://t.co/orNs0VOu2E
-
-
Mashup Score: 19SUPERNOVA Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient population - 6 month(s) ago
Positive high-level results from the SUPERNOVA Phase III COVID-19 pre-exposure prophylaxis (prevention) trial showed AstraZeneca’s sipavibart (formerly AZD3152), an investigational long-acting antibody (LAAB), demonstrated a statistically significant reduction in the incidence of symptomatic COVID‑19 compared to control (tixagevimab/cilgavimab or placebo) in an immunocompromised patient population. The trial met both dual primary endpoints; the first one being the relative risk reduction of symptomatic
Source: www.astrazeneca.comCategories: General Medicine News, RheumatologyTweet-
High level results now out for @AstraZeneca’s sipavibart from SUPERNOVA trial, meeting both primary endpoints (reduction of 1) symptomatic COVID-19 caused by any SARS-CoV-2 variant, and 2) infections caused by SARS-CoV-2 variants without F456L mutation). https://t.co/1uqDCUYrls
-
-
Mashup Score: 18
Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s Calquence (acalabrutinib) in combination with standard-of-care chemoimm unotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care in previously untreated adult patients with mantle cell lymphoma (MCL). A trend was observed in favour of Calquence plus chemoimmunotherapy for the secondary
Source: www.astrazeneca.comCategories: General Medicine News, Hem/OncsTweet-
https://t.co/eUUZVf7pXn https://t.co/dViqbG4hFV
-
Important new #CLL news PFS advantage for Acala-Ven+/-Obin vs ICT in 1L CLL. https://t.co/tRSPVlDmJY